Hepatocellular Carcinoma
Conditions
Brief summary
Clinical research of Yang Yin Fu Zheng Jie Du therapy in HBV related hepatocellular carcinoma induced anemia. The purpose of this study is to observe the efficacy of routine medical care combined with Yang Yin Fu Zheng Jie Du therapy for patients belong to HBV-HCC induced anemia.
Interventions
Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
OTHERRoutine medical care
Routine medical care
Sponsors
Beijing Ditan Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Meet the criteria of hepatocellular carcinoma * Patients who tested positive for hepatitis B surface antigen (HBsAg) for \>6 months * Meet the criteria of anemia * Ages Eligible for Study: ≤75 years old; * Informed consent from the patient.
Exclusion criteria
* Patients with upper gastrointestinal bleeding within 3 months before enrollment; * History of blood transfusion within 3 months before enrollment; * Patient with other chronic hepatopathy, such as AIH, NAFLD, ALD; * Serious problem of heart, lung, or kidney with severe dysfunction; * Pregnant or child breast feeding women; * Mental or cognitive disorders; * Participating in other drug trials; * Who are allergic to the study drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival rate | 1 year |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate | 1 year | — |
| quality of life (QOL) questionnaire | 1 year | The questionnaire includes appetite, sleep, fatigue, pain, etc. |
Countries
China
Contacts
Primary ContactZhiyun Yang, doctor
Outcome results
None listed